Asahi Kasei Pharma sponsors research for drug discovery
Asahi Kasei Pharma, a subsidiary of diversified Japanese multinational Asahi Kasei, is calling for new proposals for drug development research as part of its open innovation efforts to promote pharmaceutical research and development through cooperation with universities, research institutes and companies around the world.
Asahi Kasei Pharma established its Open Innovation Department in October 2016 with a mission to strengthen and improve global licensing and alliance building activities and has since funded about 5 proposals per year on average with a total of more than 20 proposals funded for the state of the art. state-of-the-art pharmaceutical drug developments and garnered a slew of creative new ideas. The Open Innovation team seeks to fund innovative proposals from researchers around the world up to $200,000 per year per project for this next round in 2023. Asahi Kasei Pharma will then pursue joint research opportunities with discovery researchers from drugs and their parent institutions. in hopes of creating innovative new drugs for diseases that currently have unmet needs or pioneering new platform technologies for drug discovery.
Asahi Kasei Pharma has a proven track record in the development of new drugs in the fields of autoimmune, kidney, neurological and bone diseases, so the organization can make the greatest contribution of research areas and related topics.
“Asahi Kasei Pharma believes that no one should have to give up what they would like to do because of illness,” said Osamu Matsuzaki, Senior General Manager and Head of R&D and Business Development at Asahi Kasei Pharma. “We believe great science comes from working together, and we’re thrilled to have the opportunity to accomplish this mission with researchers around the world.”
Open Innovation works to establish research collaborations related to innovative drug targets and candidate compounds up to the preclinical stage as well as advanced drug discovery technologies. Progress in exploring a new mechanism of action for the treatment of intractable autoimmune diseases is one of the most promising research results to date, with many more on the horizon. Asahi Kasei believes that these continuous efforts to advance drug discovery and research technology will further contribute to the lives and lives of people around the world.